

Ci-Ca[®] Dialysate **Plus**

A further step to high-quality Citrate CRRT



- Ci-Ca[®] Dialysate **Plus**: Easing phosphate management
- Fully integrated citrate anticoagulation with multiFiltrate Ci-Ca[®]
- Virtually interruption-free CRRT: High efficacy & easy handling
- Inherent stabilisation of serum phosphate concentration



Ci-Ca[®] Dialysate *Plus*

Inherent Stabilisation of Serum Phosphate Concentration

Citrate anticoagulation has been a major step in improving consistent provision of CRRT in critically ill patients, even with bleeding risk, by achieving effective regional anticoagulation.¹ Complete integration of citrate and calcium management into the multiFiltrate Ci-Ca[®] and a detailed protocol medically guiding the Ci-Ca[®] therapy enable its widespread clinical use.^{2,3}

Virtually interruption-free Ci-Ca[®] treatments now make CRRT truly continuous and thus very efficient. However, phosphate removal often becomes excessive, requiring phosphate substitution to prevent hypophosphataemia and its associated clinical effects such as difficult weaning from mechanical ventilation.⁴

With the physiological phosphate concentration of 1.25 mmol/L phosphate, Ci-Ca[®] Dialysate *Plus* inherently contributes to stabilising serum phosphate concentration in the physiological range and thus



Colour-coded connectors guide the user to distinguish between different fluid lines and help to avoid making wrong connections.

easing the medically essential phosphate management and thereby further adding to the safety of Ci-Ca[®] therapy.

Composition and order numbers of Ci-Ca[®] Dialysate K2 / K4 *Plus*

Name	D/GB/F/I/E/P/ NL/DK/S/N/FIN/ CZ/SRB/SK/TR Order No.	RUS/EST/ LT/LV/GR/H Order No.	Na ⁺ mmol/L	K ⁺ mmol/L	Ca ⁺⁺ mmol/L	Mg ⁺⁺ mmol/L	Cl ⁻ mmol/L	HCO ₃ ⁻ mmol/L	inorganic Phos- phate mmol/L	Glucose g/L
Ci-Ca[®] Dialysate K2 <i>Plus</i>	F00001624	F00003579	133	2	0	1	115.75	20	1.25	1
Ci-Ca[®] Dialysate K4 <i>Plus</i>	F00001625	F00003580	133	4	0	1	117.75	20	1.25	1

References

1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl* 2012; 2: 1–138
2. Morgera et al. *Crit Care Med* 2009; 37:2018 – 2024
3. Joannidis et al. *Crit Care Med* 2009; 37:2128 – 2129
4. Demirjian et al. *Nephrol Dial Transplant* 2011; 26: 3508 – 3514

The signs/names marked with ® are registered trademarks of the Fresenius Group in selected countries.

